ZTS
Zoetis Inc. Health Care Pharmaceutical Preparations S&P 500Russell 3000
$79.72Close
$33.9BMarket cap
$68.64 – $142.1252-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 15 · weaker than 85% of stocks over 12 months
- Far from its high 44% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
44%
1wk
down 1.0%
price change
1mo
up 14.9%
price change
12-month return
down 44%
market up 11% ·
its own down 54%
F-score
8 / 9
Exceptional
Altman Z
4.66
Low risk
P/E
12.7×
price / earnings
PEG
1.24
P/E / EPS growth
P/B
9.9×
price / book
Earnings yield
up 8.9%
EBIT / enterprise value
Cheaper than
61%
of the market · cheap
Revenue growth
up 2%
year on year
EPS growth
up 2%
latest quarter · -4 pts
Sales growth
0%
latest quarter · -3 pts
ROE
up 65%
return on equity
Free cash margin
up 24%
$2.3B FCF
D/E
2.65
long-term debt / equity
Net debt / EBITDA
1.6×
Interest cover
16.1×EBIT / interest
Piotroski tests
- took on more long-term debt
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- short-term liquidity improved
- no new shares issued
- gross margin widened
- assets working harder
Repair signals
- Gross margin 70.6% → 71.8%
Trade setup
ATR%
2.3%
$1.85 a day · 2×ATR $76.02
RS
15 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.99
50 sessions
Implied move
10.2%
by Nov 20, 2026 · report Nov 5, 2026
Trend template · 1 of 8
- Price above the 50-day average: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-3% vs market2 sessions after results
Options
$790,55547.8% IV · activity
Financials
- Gross 72%
- Net 28%
- Free cash 24%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.7B | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |
| Gross margin | 69% | 70% | 70% | 70% | 71% | 72% |
| Net income | $1.6B | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B |
| Net margin | 25% | 26% | 26% | 27% | 27% | 28% |
| Earnings per share | $3.42 | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
| Free cash flow | $1.7B | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B |
| Free cash margin | 25% | 22% | 16% | 19% | 25% | 24% |
| Cash | $3.6B | $3.5B | $3.6B | $2.0B | $2.0B | $2.5B |
| Long-term debt | $6.6B | $6.6B | $6.6B | $6.6B | $5.2B | $9.0B |
| Shareholders' equity | $3.8B | $4.5B | $4.4B | $5.0B | $4.8B | $3.4B |
| Shares outstanding | 475.32m | 472.57m | 463.81m | 458.37m | 448.47m | 424.93m |
Next report
Nov 5, 2026 · before the open
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±10.2%
$71 – $87 by Nov 20, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±9.4%
last 4: -2.3% · -25.5% · -1.6% · -16.5%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
About usual
1.1× the usual move
What options price now
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 47.8% priced · 27.8% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $790,555 calls $570,962 · puts $219,592 · latest session
- 0.38× +0.04 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +1.17k · puts +1.83k past week
For options traders: ATM IV 47.8% (+4.2% 1w) · 1m ÷ 3m IV 1.27 · 25Δ skew -1.5 pts · Net GEX $4.9M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 12, 2026 | Annual ↗ | Dec 31, 2025 | 43d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 13, 2024 | Annual ↗ | Dec 31, 2023 | 44d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 13, 2026 | Director or officer change · Regulation FD ↗ |
| Oct 8, 2026 | Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| Aug 6, 2026 | Director or officer change ↗ |
| May 22, 2026 | Director or officer change · Shareholder vote ↗ |
| May 20, 2026 | Regulation FD ↗ |
| May 7, 2026 | Results ↗ |
| Feb 12, 2026 | Results ↗ |
| Feb 5, 2026 | Regulation FD ↗ |
| Dec 18, 2025 | Material agreement · New obligation · Unregistered share sale · Regulation FD ↗ |
| Dec 11, 2025 | Regulation FD ↗ |
| Dec 2, 2025 | Other events ↗ |